AS­CO ab­stracts mint some ear­ly win­ners, but Io­vance, Spring­Works get hit by mas­sive loss­es

Be­fore can­cer-fo­cused biotechs start their trek to the first in-per­son Amer­i­can So­ci­ety of Clin­i­cal On­col­o­gy (AS­CO) an­nu­al con­fer­ence since the pan­dem­ic be­gan, in­vestors have tak­en a good look at the teasers for the da­ta sched­uled to be pre­sent­ed — and start­ed plac­ing bets.

With its pow­er to con­fer overnight fame, AS­CO is a stage where im­pres­sive or sur­prise de­but per­for­mances can go a long way. On the oth­er hand, dis­ap­point­ing de­tails could be pun­ish­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER